AIMS: To validate the Spanish version of the University of California Performance Skills Assessment (UPSA) in patients with severe mental disorders. METHODS: Naturalistic, 6month follow-up, multicentre, validation study. 139 patients with schizophrenia, 57 bipolar patients and 31 controls were evaluated using the following scales: Spanish UPSA (Sp-UPSA), Clinical Global Impression, Severity (CGI-S), Global Assessment of Functioning (GAF), and Personal and Social Performance (PSP). RESULTS: Reliability: Internal consistency (Cronbach's alpha) was 0.81 in schizophrenia and 0.58 in bipolar patients. Test-retest was 0.74 and 0.65 (p<0.0001) respectively. Construct validity: Pearson correlation coefficients between Sp-UPSA and PSP total scores were 0.42 (p<0.0001) for schizophrenia and 0.44 (p=0.001) for bipolar patients. For Sp-UPSA and GAF scores correlation coefficients were 0.43 and 0.52 (p<0.0001) respectively. Discriminant validity: The Sp-UPSA discriminated between patients and controls. In schizophrenia patients it also discriminated among different levels of illness severity according to CGI-S scores. In control versus patients with schizophrenia contrasts, the area under the curve was 0.89 and a cut-off point of 85 provided a sensitivity of 82.7% and a specificity of 77.4%. In bipolar patients, the area under the curve was 0.85 and a cut-off point of 90 provided a sensitivity of 82.5% and a specificity of 64.5%. CONCLUSION: The Spanish UPSA is a reliable and valid instrument for assessing functional capacity in severe mentally ill patients. It seems to be appropriate for use in clinical trials and in everyday clinical practice as a means of monitoring functional outcomes.
AIMS: To validate the Spanish version of the University of California Performance Skills Assessment (UPSA) in patients with severe mental disorders. METHODS: Naturalistic, 6month follow-up, multicentre, validation study. 139 patients with schizophrenia, 57 bipolarpatients and 31 controls were evaluated using the following scales: Spanish UPSA (Sp-UPSA), Clinical Global Impression, Severity (CGI-S), Global Assessment of Functioning (GAF), and Personal and Social Performance (PSP). RESULTS: Reliability: Internal consistency (Cronbach's alpha) was 0.81 in schizophrenia and 0.58 in bipolarpatients. Test-retest was 0.74 and 0.65 (p<0.0001) respectively. Construct validity: Pearson correlation coefficients between Sp-UPSA and PSP total scores were 0.42 (p<0.0001) for schizophrenia and 0.44 (p=0.001) for bipolarpatients. For Sp-UPSA and GAF scores correlation coefficients were 0.43 and 0.52 (p<0.0001) respectively. Discriminant validity: The Sp-UPSA discriminated between patients and controls. In schizophreniapatients it also discriminated among different levels of illness severity according to CGI-S scores. In control versus patients with schizophrenia contrasts, the area under the curve was 0.89 and a cut-off point of 85 provided a sensitivity of 82.7% and a specificity of 77.4%. In bipolarpatients, the area under the curve was 0.85 and a cut-off point of 90 provided a sensitivity of 82.5% and a specificity of 64.5%. CONCLUSION: The Spanish UPSA is a reliable and valid instrument for assessing functional capacity in severe mentally illpatients. It seems to be appropriate for use in clinical trials and in everyday clinical practice as a means of monitoring functional outcomes.
Authors: Eneritz Bengoetxea; Cynthia Z Burton; Brent T Mausbach; Thomas L Patterson; Elizabeth W Twamley Journal: Psychiatry Res Date: 2014-04-13 Impact factor: 3.222
Authors: Brent T Mausbach; Denisse Tiznado; Veronica Cardenas; Dilip V Jeste; Thomas L Patterson Journal: Psychiatry Res Date: 2016-08-08 Impact factor: 3.222
Authors: Jesús J Gomar; Elia Valls; Joaquim Radua; Celia Mareca; Josep Tristany; Francisco del Olmo; Carlos Rebolleda-Gil; María Jañez-Álvarez; Francisco J de Álvaro; María R Ovejero; Ana Llorente; Cristina Teixidó; Ana M Donaire; Eduardo García-Laredo; Andrea Lazcanoiturburu; Luis Granell; Cristina de Pablo Mozo; Mónica Pérez-Hernández; Ana Moreno-Alcázar; Edith Pomarol-Clotet; Peter J McKenna Journal: Schizophr Bull Date: 2015-05-25 Impact factor: 9.306
Authors: Raeanne C Moore; Emily W Paolillo; Anne Heaton; Pariya L Fazeli; Dilip V Jeste; David J Moore Journal: PLoS One Date: 2017-08-24 Impact factor: 3.240
Authors: J Peña; P Sánchez; E Elizagárate; N Ibarretxe-Bilbao; J Ezcurra; L Caballero; M Magariños; I García Del Castillo; M Gutiérrez; N Ojeda Journal: Schizophr Res Cogn Date: 2015-12-17
Authors: Susana Al-Halabí; Pilar A Sáiz; Marlén Garrido; Gonzalo Galván; María José Casares; María Teresa Bobes-Bascarán; Eva M Díaz-Mesa; Patricia Burón; Leticia García-Álvarez; Javier Suárez-Álvarez; José Muñiz; M Paz García-Portilla; Julio Bobes Journal: Int J Clin Health Psychol Date: 2015-08-25
Authors: Shelagh Szabo; Elizabeth Merikle; Greta Lozano-Ortega; Lauren Powell; Thomas Macek; Stephanie Cline Journal: Schizophr Res Treatment Date: 2018-12-27